文献速递淋巴瘤

基于H&E组织学的套细胞淋巴瘤人工智能预后指数

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.
PubMed 文献 · Leukemia · 2026-07-07

研究开发了MAIPI,一种仅基于H&E染色活检图像训练的深度学习算法,用于评估套细胞淋巴瘤患者预后。训练集为428例临床试验患者,独立验证集为140例接受免疫化疗(含或不含伊布替尼)的患者。MAIPI可自主选择兴趣区域,提供独立于MIPI和Ki67的预后信息,无需分子检测或专家病理评估。

要点

  • MAIPI仅需H&E图像即可预测套细胞淋巴瘤预后
  • MAIPI预后信息独立于MIPI和Ki67
  • 无需分子检测或专家病理学家评估

核心结论

  • MAIPI是一种仅基于H&E图像训练的深度学习算法,可提供独立于MIPI和Ki67的套细胞淋巴瘤预后信息。

研究设计与样本

  • 深度学习算法训练于428例临床试验套细胞淋巴瘤患者的诊断性活检H&E图像。
  • 在140例接受免疫化疗(含或不含伊布替尼)的独立队列中验证预后预测能力。

主要发现

  • MAIPI可自主选择兴趣区域并提供预后信息。
  • MAIPI的预后信息独立于MIPI和Ki67。
  • MAIPI无需分子检测或专家病理学家评估。

临床怎么用

  • MAIPI可仅基于H&E图像辅助套细胞淋巴瘤风险分层,无需分子检测或专家病理评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical course of Mantle Cell Lymphoma (MCL) varies between individual patients. Early detection of risk is crucial to assign MCL patients to novel treatment strategies. Most of the established biomarkers of outcome require specifically trained pathologists or molecular analysis. Here we introduce MAIPI (MCL Artificial Intelligence Prognostic Index), a deep learning algorithm trained only on Hematoxylin and Eosin (H&E) images of diagnostic biopsies of n = 428 MCL patients from clinical trials to assess prognosis. The capability of MAIPI to predict disease outcome was validated in an independent cohort of n = 140 patients treated with immunochemotherapy with and without ibrutinib. MAIPI selects areas of interest by itself and provides prognostic information independent of the MCL International Prognostic Index (MIPI) and Ki67 and without the need of molecular testing or expert pathologists evaluation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lippl J, Reinke S, Koch K, et al. Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology. Leukemia. 2026. PMID: 42414604. doi:10.1038/s41375-026-03036-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。